Properties of new drug for Eczema
-
- Most prescriptions are steroid ointments.
- High efficacy drug with no side effect
- Low recurrence rate
-
Problems of existing treatments
- Risks of causing newborn malformation for current drug
- Current drug was approved as a second-line therapy for chronic severe hand eczema in adults who do not respond to strong topical steroid therapy for at least 4 weeks.
- Due to safety concerns, it can only be administered for up to 24 weeks.
- Low efficacy (45%) with high recurrence
Characteristics of
the target drugs
- Excellent efficacy in short treatment time
- Established safety and no side effects with natural ingredients
- Oral administration
- The mechanism of action is suppressing the abnormal immune responses.
Competitiveness of the FB718A1
Animal efficacy experiment Suppression of
"Itching, swelling, erythema, scale, epidermal peeling, skin thickness"
Mechanism of Action for FB718A1
- Confirmation of maintaining balance
of Th1 / Th2 related cytokines
- Animal experiments
for efficacy and MoA
Important biomarkers of eczema were improved.
“decreased levels of IgE, IL-4, IL-10 and increased level of IFN-γ in serum”
Competitiveness of the FB718A1
Eczema treatment
FB718A1
-
Specialty
Identification of MoA
Identification of
mechanisms
related to
immune function
Safe natural drug
Safety confirmed by
preclinical trials
Oral treatment
Convenient administration
No side effects
Excellent efficacy and
rapid treatment effect
Higher than 90%
therapeutic effect after
3 weeks of administration
-
Marketability
Big Market Size
Present: $4.88 billion
2022: $5.63 billion
-
Monopoly
Secured intellectual
property rights
Domestic patent
registration completed
Completed 5 overseas applications
(Securing global rights)
